Telios
This article was originally published in The Gray Sheet
Executive Summary
Submits premarket approval application for Telio-Derm wound healing agent for the treatment of chronic dermal ulcers associated with diabetes. A study supporting the PMA filing showed a "fourfold increase in the number of ulcers completely healed in the Telio-Derm group compared to the control group," according to the company. Telios also plans to apply its technology to the treatment of ophthalmic and other types of severe and chronic dermal wounds.